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ABSTRACT 
Presymptomatic and predictive genetic testing should involve a considered choice, 
which is particularly true when testing is undertaken in early adulthood. Young adults 
are at a key life-stage as they may be developing a career, forming partnerships and 
potentially becoming parents: presymptomatic testing may affect many facets of their 
future lives. The aim of this integrative systematic review was to assess factors that 
influence young adults’ or adolescents’ choices to have a presymptomatic genetic test 
and the emotional impact of those choices. Peer-reviewed papers published between 
January1993 to December2014 were searched using eight databases. Of 3373 studies 
identified, 29 were reviewed in full text: 11 met the inclusion criteria. Thematic analysis 
was used to identify five major themes: period prior to testing, experience of genetic 
counselling, parental involvement in decision-making, impact of test result 
communication, and living with genetic risk.  Many participants grew up with little or no 
information concerning their genetic risk. The experience of genetic counselling was 
either reported as an opportunity for discussing problems or associated with feelings of 
disempowerment. Emotional outcomes of disclosure did not directly correlate with test 
results: some mutation carriers were relieved to know their status, however, the 
knowledge they may have passed on the mutation to their children was a common 
concern. Parents appeared to have exerted pressure on their children during the 
decision-making process about testing and risk reduction surgery. Health professionals 
should take into account all these issues to effectively assist young adults in making 
decisions about presymptomatic genetic testing. 
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INTRODUCTION 
Presymptomatic and predictive genetic testing are available for a number of heritable 
genetic disorders including hereditary cancer syndromes, inherited cardiac conditions 
and neurodegenerative genetic disorders1. The terms  ‘presymptomatic’ and ‘predictive’ 
genetic testing refer to the possibility of detecting a genetic mutation that causes a 
particular condition before the presentation of symptoms. The first term generally refers 
to those diseases in which a positive test result will inevitably lead to the development 
of the disease later in life (e.g. Huntington disease); the second term refers to a 
broader range of diseases in which the risk for a disorder is increased but without 
necessarily implying any degree of certainty (e.g. hereditary breast and ovarian 
cancer). However, these terms are often used in a broadly interchangeable manner. A 
substantial difference is that cancer disorders can be monitored through a surveillance 
protocol or prevented by surgical intervention, while no prevention is currently available 
for diseases such as Huntington disease or cerebellar ataxia. Therefore, the choice to 
undergo a presymptomatic test for disorders with incomplete penetrance and where 
there are preventive measures could have a highly different psychological and social 
impact when compared to testing for disorders with complete penetrance and no 
preventive options, particularly in young adults. In this review, the term 
‘presymptomatic’ will be used to indicate both predictive and presymptomatic tests, but 
the different impact will be considered whenever appropriate. 
A presymptomatic diagnosis of a serious genetic illness can have a profound impact on 
the person and family and should be managed using an individualized counselling 
process1. Presymptomatic genetic testing of minors (under the age of 18 years) is not 
usually recommended unless effective clinical actions are available2–4 . Generally, 
there are three key arguments against presymptomatic genetic testing in adolescents 
or young people:  that it (1) fails to respect the future autonomy of the young person; 
(2) breaches confidentiality; and (3) may cause psychosocial harms5. 
The age at which young people should undergo presymptomatic genetic testing for 
adult-onset disorder is a matter of debate2–5. Key challenges have to be faced during 
the transition from adolescence to adulthood, such as marriage, finishing education, 
beginning full-time employment and becoming a parent, and the impact of testing may 
affect, and be affected by each of these events. In the light of the above-mentioned 
issues, it would be appropriate to ask what health information and counselling young 
adults need to make prudent decisions about genetic testing. The purpose of this 
systematic review was therefore to systematically identify and analyse factors 
influencing young adults’ or adolescents’ choices to have a presymptomatic test and 
the emotional impact of those choices. 
METHODS 
Design 
A systematic review is a method of amassing, assessing and synthesizing a body of 
evidence on a particular topic6. This systematic review was conducted in accordance 
with the Centre for Reviews and Dissemination methods for undertaking reviews in 
health care6 with the aim of assessing which factors influence young adults’ or 
adolescents’ choices to have a presymptomatic test for a genetic condition and the 
emotional impact of those choices. 
Search strategy 
Eight databases used for indexing medical and psychosocial research (Embase, 
Medline, PsychoInfo, Pubmed, SocIndex, The Cochrane Library, Cumulative Index of 
Nursing Allied Health Literature (CINAHL) and Web of Science) were searched for 
papers published between January 1993 and December 2014. We chose to start at 
1993 because presymptomatic testing based on mutation analysis (i.e. not based on 
linkage) became available for Huntington disease that year (Harper et al., 1993) and 
this was a landmark in presymptomatic testing for adult onset conditions. As the first 
authors are bilingual, papers published in either English or Italian were eligible (there 
were no papers identified that were written in Italian).  The literature search employed 
variations and Boolean connectors of the key terms. An exploratory search with the 
terms “genet*” or “predict* test*” or “presymptom* test*” or “young*” or “adult*” or 
“adolescent*” or “decision*” or “choic*” or “communicat*” or “psycho*” resulted in 976 
studies, which failed to include some papers already known on this theme, therefore a 
further search was conducted by using the key terms: “adolescent*” or “young*” or 
“BRCA” or “APC” or “Lynch” or “Huntington” or “genetic* test*”. Targeted internet 
searching using Google Scholar and reference lists of relevant papers were also 
examined for any additional studies of interest. 
Inclusion and exclusion criteria 
The criteria for inclusion in this systematic review were papers: a) published in English 
or Italian; b) published in peer-reviewed journals between 1993-2014 and reporting 
original research (using any methods); c) where the study sample explicitly included 
young adults or adolescents (14-30 years); d) focused on presymptomatic or predictive 
testing in young people; e) focused on the factors influencing young adults’ or 
adolescents’ choices to have a presymptomatic or predictive test and the emotional 
impact of those choices. Papers were excluded from the review if they were: a) 
guidelines for testing; b) educational or opinion papers; c) focused on perceptions and 
attitudes of college students/young adults who were not at known risk of a specific 
adult-onset genetic condition. 
Selection of studies 
Three review authors (LG, LJ and DT) independently screened the titles and abstracts 
of articles identified in the first search against the inclusion criteria and decided which 
papers should be retrieved. Articles were rejected at this stage if the title or abstract did 
not focus on our topic, was not in English or Italian, or was not original research. We 
reviewed selection decisions and resolved disagreements by consultation with a third 
review author (HS).  
Search outcome 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA7 
flowchart showing the consecutive methodological steps of this systematic review is 
displayed in Figure 1. The search of eight databases initially produced 976 potential 
papers. With the second search, 2397 papers were found. On the total of 3373, 755 
were duplicates, leaving 2618 for examination. Following review of the title and 
abstract, 29 papers were assessed as potentially relevant. These papers were read in 
detail by the authors. Eleven papers were included in the review. The main 
characteristics of the included studies are described in Table 1.  
Quality appraisal 
All papers considered for inclusion in the review were subjected to independent 
analysis by two authors (LG and HS) using standard quality assessment criteria for 
evaluating original research papers from a variety of fields8. This evaluation method 
allows the systematic evaluation of both quantitative and qualitative original research 
and across a broad range of study designs. Specific aspects of the paper, relating to 
methodology and reporting of results are assessed and assigned 0 points (not 
addressed), 1 point (partially addressed) or 2 points (satisfactorily addressed). A 
summary percentage score was calculated by dividing total score summed across all 
applicable items by the highest possible score total after excluding non-applicable 
items8. Any disagreements about scoring of papers were discussed. Kmet et al8 do not 
enforce a minimum score for inclusion in a review, although they suggest 60% as a 
reasonable cut-off point. In the present review two papers scored 50%, but it was 
decided to include them, since they contributed relevant information that was not 
included in the other papers (see Table 1).  Thus, all papers contributed to the 
synthesis and development of themes. 
Data abstraction and analysis 
It was not possible to undertake a meta-analysis of the data due to the heterogeneity of 
the methods and samples.  We therefore prepared a narrative description of the 
findings6 using thematic analysis based on the methods described by Braun and 
Clarke9, in order to employ a clear, replicable, and transparent methodology. The 
thematic analysis was confirmed by three authors (LG, DT, HS).  
RESULTS 
Characteristics of included studies 
In total, the systematic review included 11 qualitative studies. Methods adopted by the 
authors were: interpretative phenomenological analysis10, thematic analysis 11–15, a 
combination of interpretative content analysis and thematic analysis16, or grounded 
theory16–20.  Patenaude et al15 also included a quantitative analysis of their data. 
All the included studies were published between 2007-2014 and were focused on few 
specific heritable disorders, namely autosomal dominant cerebellar ataxia14, familial 
adenomatous polyposis (FAP)12,16, familial cardiomyopathy10, hereditary breast and 
ovarian cancer (HBOC)10,13–15,17–20, hereditary diffuse gastric cancer14, Huntington 
disease 2,11,14,16 and Lynch syndrome14. Samples included participants within an age 
range of 12-39 years, thus including, but not limited to, the age range of 14-30 years 
identified by the authors as the focus of the search. Eligible studies were conducted in 
Australia11,12,14,16, Canada13,17,18, United Kingdom10, and the United States15,17–19. 
Findings of the analysis 
Issues emerging from young people interviews included family and partner 
relationships, plans for the future, emotional state and the general approach to life.  
Five major themes were identified: the period prior to testing, the experience of genetic 
counselling, involvement of parents in decision-making, impact of personal test result 
communication and living with genetic risk. 
The period prior to testing 
Many participants reported having grown up without awareness or with misinformation 
about the genetic disease running in their family or its inheritance mode11,15,20: they also 
lacked information about the appropriate age for testing11,15.  
Two sets of authors reported that the first communication about the genetic risk was 
made by parents13,15. None of the participants was younger than 12 years of age when 
informed, about half experienced disclosure before they were 18 years old and half 
between 18 and 21 years old. Many participants stated that the disclosure was made 
during an occasional encounter and in a casual moment (i.e. while driving) or by 
telephone15. Almost all daughters were informed of their mother’s test result in a private 
conversation with their mother, and it was rare for both parents to participate in the 
disclosure13,15. In some studies, participants expressed a preference toward being 
informed by both parents, although they knew that the information given by parents 
was limited and sought genetic counselling almost immediately after disclosure13. In 
other cases, once aware of the family genetic disorder, those who did not understand 
what it really meant sought information online or in professional journals15, while those 
who were more conscious of own risk (or potential risk) arranged the first counselling 
session to have their blood test17. 
However, interviewees described the disclosure of a positive parental test result as the 
most important information of their lives14, reporting concerns about their mother’s 
health14,15 and, only secondarily, their own14. In the quantitative sub-study by 
Patenaude et al15, one third of the daughters of BRCA1/2 mutation carriers reported 
normal levels of general distress but high cancer-related distress, which was not 
significantly different from distress levels of women with known BRCA1/2 mutations. 
Some participants reported that at the time they were told of their risk, the implications 
for themselves seemed distant, but now, as young adults, the fear of developing the 
adult-onset disease recurring in their family had increased15.  Conversely, others felt 
that early disclosure of the family disease gave them the time to digest the 
information13. However, the knowledge of being at risk of a disorder such as Huntington 
disease for some participants involved engagement in risk behaviours such as drugs 
use, trouble with the police or difficulty at school11.  
When approaching the decision about testing, in the study by MacLeod et al10 most of 
the participants did not understand that having a presymptomatic test was a choice, but 
rather something they felt obliged to undergo in order to obtain information about 
themselves and to remove uncertainty.  For example, a young woman said ‘I knew, I 
had to’ (p 397)10. By contrast, those who perceived there was a choice prepared 
themselves for the result; some prepared themselves for the worst possible outcome 
because then they would not be surprised by bad news10,11,14, while other participants 
were scared that receiving the test result would be devastating15. Some study 
participants expected to test positive because of identification with a gene-positive 
family member10,13,14. 
Choosing to undergo genetic testing constituted a major life event12, so important that 
participants reported it had a significant impact on their outlook and sense of self14,16. 
For example, a young woman said ‘that was the day the clock stopped; that was the 
day the uncertainty began’ (p 644)14. Nevertheless, while Mand et al14 and MacLeod et 
al10 report that no interviewees expressed regret regarding the decision to undertake 
testing, the timing for testing emerged as important because of potential interference 
with schooling: one young woman tested during her final year, said that looking back, 
she wished she had been tested at a different time  of her life16. Another factor relevant 
to the timing of testing was childbearing planning10,13, with participants split on the issue 
of undergoing presymptomatic testing prior to versus after having children13. 
The experience of genetic counselling 
Undergoing genetic counselling for the young adults studied by Duncan et al16 was 
reported to have helped discussion of problems, for example a young woman who was 
mutation positive for Huntington disease said that the counsellor helped her with every 
type of problem in her life. Even when the genetic counselling was a source of 
information and support, it did not appear to facilitate the decision to be tested10. 
However, Duncan et al12 showed that when counselled and tested at the same time as 
their siblings, participants felt this had limited the individual attention and support 
during the counselling process.  
Some negative feelings were reported about counsellors14, such as the perception of 
not being understood and the feeling that the counsellor was the person with the power 
over the testing decision. Some participants were disappointed to hear that the 
counsellor believed they were not ready to deal with the psychological consequences 
of the genetic test and that they needed to take time to reach an autonomous decision. 
The need to wait for genetic testing increased the feeling of disempowerment raised by 
uncertainty: a girl said ‘I wanted the maybe to become yes or no; I was over maybe’ (p 
645)14. Others focused their attention on the procedure, instead of the meaning of 
testing, with the fear of the needle overshadowing the purpose of the counselling12,16.    
A consequence of discussion during pre-test counselling was that most young adults 
had shared their test result with only close friends and family, because they felt that 
other people would not understand the complexities of the process from decision-
making to the result10. 
Involvement of parents in decision-making 
Although theoretically an autonomous choice to undergo presymptomatic testing is a 
fundamental requirement of the process of genetic counselling, some parents were 
reported to exert pressure on their young adult children10–12,16,17,19.  In addition, Hoskins 
et al20 reported that a young woman underwent genetic testing because of her 
gynaecologist’s suggestion. As a consequence of parental pressure, interviewees 
conveyed feelings of disempowerment and lack of control and declared that they 
underwent genetic testing because of pressure from family members or “for” a parent, 
which also raised the ethical problem of respecting young adults’ developing 
autonomy11,12,16,17,19. A young boy said “I was 12 when I was told that I had to have the 
test, I didn’t want to have it, but then I sort of had to” (p 30)12; a girl said that her 
parents did not ask her if she wanted to do, they just said “you know, you have to go 
get a blood test” (p 30)12. 
Older participants were more likely than younger ones to decide autonomously to have 
genetic testing, so much so that some described it as ‘a way to take control and not to 
be like their mothers’ (p 152)18.  
Even when the decision-making was autonomous and pragmatic, still the family 
experience was important, especially when parents had developed cancer17. Some of 
these young adults had lost a parent in their adolescence or earlier, so they grew up 
without a parent and with the knowledge that their parent’s death was due to “the gene” 
and that they may carry the same risk.  In this way, the study conducted by Hamilton et 
al17 showed that participants both desired and feared genetic testing. Another key 
motivation was the perception that they were doing something to alter the course of a 
disease that had led to the death of affected relatives10. A young woman said ‘I just 
thought that you know if she (mum) would have had the opportunity to have the test, 
then things could have been a lot different’ (p397)10. 
However, differences emerged in parental involvement in the decision-making process, 
based on the specific disease10. Parents in families with familial cardiomyopathy had a 
strong influence in favour of testing; in HBOC the decision was autonomous but usually 
congruent with the parents’ point of view, while in HD the decision was autonomous 
and sometimes went against the parents’ opinion10. 
Impact of personal test result communication 
Once the test was undertaken, waiting for test result was associated with anxiety16. At 
the time of the communication of the genetic test result, participants generally had to 
face the idea of disease13. Usually at their age young adults do not think about disease; 
their attention is focused on plans for their future such as university and/or job plans13.  
Nevertheless, none of the participants of the study by Mand et al14 reported a 
catastrophic emotional response to their test result, but conflicting emotions of relief, 
happiness, guilt, fear and anger were generally reported13. In more detail, authors 
described the emotional impact of both gene-negative and gene-positive test results. 
Surprisingly, positive and negative emotional outcomes were not correlated with test 
results: in any case interviewees thought that the best thing was to find out the result16. 
Accordingly, participants described themselves as happy just to know their genetic 
status or as willing to begin enjoying life and to make behavioural changes11,14. 
Specifically, a positive result led participants to feel able to move forward and to 
understand what was important (or not) in their lives16. Although some participants 
stated their positive result induced a change of lifestyle, others showed no reaction to 
testing positive; this lack of reaction sometimes created uneasiness because the 
counsellors failed to understand the underlying feelings, which are well explained by a 
girl: “I kept on the same direction I was already going” (p 646)14. In others, a gene-
positive result created some negative emotions such as depression and anxiety, either 
in general or related to potential gossip by other people14,16, connected with 
employment16,  related to the possibility of passing on the mutation to their future 
children14 or because of a different test result in other family members10. A young boy 
said “ when I first found out I didn’t want be too happy around them because it’s still not 
the best of situations because my mum’s still poorly with it[…], I still upset about my 
mum” (p 399)10; a girl said that she had been only thinking of herself during the 
decision-making process, but now, receiving a negative test result, she wondered 
“what does she (sister) feel about me now because I haven’t got it and she has” (p 
399)10. In addition, some interviewees described their shock at finding out that they had 
not inherited the family mutation10,14: they had prepared themselves for something and 
then it just did not happen10,11. This was particularly true for young adults receiving an 
HD result10. One young man, in the study by Macrae et al13, received a negative test 
result but clearly expressed the desire to have been mutation-positive. Also, negative 
test results generated unexpected negative emotions in some participants, such as 
guilt and feeling distanced from family members. Moreover, some interviewees 
expressed the desire to receive additional screening regardless of their results, 
because  of their familial cancer experience and residual cancer worry13. Nevertheless, 
in other participants the negative test result was associated with feeling able to plan for 
the future16.  
Living with a genetic risk 
Although the authors of seven papers analysed risk management in terms of behaviour 
and attitudes, six of those papers were focused on BRCA1/2 carriers or daughters of 
BRCA1/2 carriers10,13,15,17–20 and only one on familial cardiomyopathy and HD10. 
Even though interviewees stated that having time before the beginning of surveillance 
age gave them the opportunity to think about surveillance protocols or prophylactic 
surgery13, younger participants were more likely to feel out of place in the health care 
system and frustrated at their inability to access screening, so much so that some 
described themselves as ‘paralyzed’: one young woman underwent bilateral 
mastectomy at age 22, believing it was the only way to manage her cancer risk20. 
Others expressed frustration at receiving inconsistent, inaccurate, ambiguous or 
incomplete recommendations by genetic counsellors or doctors, during the initial phase 
of their mutation-positive experience20. They complained that each doctor explained 
only their own discipline-specific perspective and knowledge base. 
Others wondered about when to share with a new partner their genetic risk or how 
early in a relationship to discuss having children10,15,18–20 or plans for prophylactic 
surgery15,18,19.  
Some participants with children described the impact of knowing they may have 
passed on the mutation to their children in terms of feeling guilty, worried and, in some 
cases, leading to a decision to limit the number of children.  However none regretted 
the choice to have children18; they declared that they first considered the possibility of 
avoiding having children, but then realized that there were many options and over time 
there will hopefully be more18. However, participants with children thought also about 
‘staying alive’ related to their children (p 28)18 or of being not the next in the family17. As 
a consequence of the wish to stay alive, young women were making the choice to have 
prophylactic surgery sooner rather than later17,18. On the other hand, those opting for 
surveillance did not feel confident in surveillance protocols and reported of being 
anxious waiting for the next screening17. A 35 year old woman said ‘I admire women 
who can live with surveillance, but that was not for me’ and she felt herself as being a 
‘ticking time bomb’ (p 153)17.  
Werner-Lin et al19, also, showed that some parents exerted pressure on their children 
to pursue risk reduction surgery, while other young adults erected a barrier, because of 
their young age, to addressing aspects of cancer risk, for example in terms of being too 
young for surveillance.  
DISCUSSION 
Although this systematic review focused on presymptomatic testing, one major issue 
emerging from the papers reviewed is when and how at-risk individuals are informed of 
their genetic risk. Although many participants grew up with no or scarce information 
concerning their potential genetic risk, communication generally occurred due to the 
parents’ initiative and in a casual manner, several years before testing or clinical 
actions could be undertaken11,15,20. This is in line with findings by Rew et al21, which 
showed that the majority of children of BRCA mutation carriers learnt of their potential 
genetic risk of cancer many years before preventive interventions were recommended. 
Indeed, intra-familial communication is a highly complex process, especially when an 
inherited genetic condition is involved, thus it is understandable that parents face the 
dilemma of when, how and what to tell their children about it22,23. On the other hand, 
appropriate communication of genetic risk information by parents to their children is 
highly desirable, since it has been shown to have long-term consequence in terms of 
informed reproductive decision-making and better family cohesion24. To achieve this, 
health professionals may have a role in both supporting parents and young people, but 
their involvement in parents’ decisions to communicate genetic risk to young family 
members was found to be limited in both our search and previous reports21,25,26. 
Although this may be partly due to the parents’ wish to undertake this task alone, it is 
reported that some parents desired health professionals to be available in a supporting 
role, but found that this support was limited24,27. This evidence highlights the need for a 
comprehensive, longitudinal counselling process with appropriate timing and setting, 
which supports ‘parent-to-offspring ’ risk communication first and young people’s  
decision-making about presymptomatic testing and risk management afterwards. 
Accordingly, participants perceived that their lack of emotional experience at the time of 
testing had made it difficult for them to envisage the possible psychological impact of a 
test result10. Furthermore, establishing a deeper and long-standing relationship with the 
counsellor may reduce the feelings of disempowerment reported by some study 
participants about the experience of genetic counselling. Such an approach would also 
help limit parents’ pressure towards testing or risk-reducing surgery, which was a 
relevant issue in the studies reviewed10–12,16,17,19.  
Concerning the impact of test results, overall, our findings do not support any 
substantial risk of adverse emotional outcome in mutation carriers, which is in 
agreement with previous findings28. However, possible reactions to being tested per se 
should be explored before undertaking testing, instead of focusing only on the potential 
effects of specific test results.  
Nevertheless, there is general concern that undergoing presymptomatic testing too 
early in life may increase the risk of unfavourable impact, and, therefore, the right age 
to undergo presymptomatic testing is still a matter of debate29–31. In most of the papers 
analysed, the age at which participants had undergone genetic testing was not 
specified12,13,15,17–19, whereas Duncan et al16, who included in their analysis 10 
individuals who were aged 10-17 years at the time of their genetic test for FAP, 
concluded that harms observed in younger persons were no different in nature from 
those described in adults. According to UK guidelines, people aged 16 or 17 are 
presumed to be capable of consenting to their own medical treatment, and, in specific 
cases, children under 16 years who have sufficient understanding and intelligence to 
enable them to fully understand what is involved in a proposed intervention will also 
have the capacity to consent to that intervention32. Conversely, according to 
international guidelines4, presymptomatic testing for adult-onset disorders are 
recommended to be made available to those aged 18 years and older, unless there it is 
in a child’s best interest either in terms of immediate relevance for their health or of 
psychological or social benefits. Nevertheless, Richards argued that young persons 
who are considered as adults on the age-based criterion of 18 years are not all 
necessarily truly autonomous30. She pinpointed that the most important aspect of the 
decision-making process was the recognition that the knowledge obtained from the test 
result is irreversible.  There is not a specific age when a person is able to give 
autonomous consent, but it is important to consider psychological maturity30 that is 
cumulative with age, life experience and cognitive development33. Therefore, future 
studies should aim at defining the optimal moment when to undergo presymptomatic 
genetic tests, not only on the basis of the age, but also considering psychosocial 
maturity34. In any case, genetic healthcare professionals, in the context of 
presymptomatic counselling, should support young adults to become aware of their 
own individual needs and capacities and of the fact that, sometimes, waiting to be 
tested  may be helpful to better understand potential harms and benefits of testing.   
In addition, although it is reasonable to hypothesize that undergoing testing at the right 
time reduces the risk of negative effects, it is important to consider the influence of the 
specific disease considered: the perception and experience of harms and benefits from 
the test result for a potentially treatable condition (such as BRCA, FAP, etc.) may not 
be the same as for conditions for which there are no preventive treatment or cure (such 
as HD).  
A potential limitation of this systematic review is that all the papers analysed are based 
on studies conducted in only four countries with similar British historical and cultural 
legacies, thus the findings may not generalize to other countries with different 
sociocultural backgrounds, supporting the need for further studies in other contexts. On 
the other hand, the papers analysed spanned across several diseases, while 
considering similar age ranges, thus providing a comprehensive overview of how 
young adults deal with genetic testing overall and according to the specific disease. 
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FIGURE 1 PRISMA FLOWCHART OF STUDY SELECTION. This PRISMA flowchart 
demonstrates the process of identifying and screening relevant studies. The screening 
process identified 11 studies from an initial pool of 3373 as being relevant to the 
current review 
 
 
 
- 2 abstracts not found 
- 35 not in Italian or English 
- 2 wrong publication year 
- 125 books/ dissertations 
- 225 age-range not fitting 
- 37 not original research 
- 70 not on factors influencing young 
adult’s choice to have predictive test 
- 2093 not on the topic 
 
S
cr
e
e
n
in
g
 
In
cl
u
d
e
d
 
E
li
g
ib
il
it
y
 
Id
e
n
ti
fi
ca
ti
o
n
 
Records identified through 
database searching  
n = 3373 
Records after 755 duplicates removed 
 n =  2036 
Records screened 
n =  2618 
Records excluded 
n =  2589 
Full-text articles 
assessed for eligibility 
n = 29 
 
Full-text articles 
excluded, with reasons 
n= 18 
Studies included in 
qualitative synthesis 
n = 11 
- 7 on communication to children of 
parents results, not on testing 
- 2 on testing children 
- 1 focus  on twins 
- 1 paper without ethical approval, 
consent, etc 
- 1 not on genetic risk 
- 2 not on predictive testing 
- 3 age-range not fitting 
- 1 views of mothers of young people 
 
Table 1. Table of studies included in the review 
Table 1 Main characteristics of included studies 
Study Country 
Number of 
participants 
Age Condition Aim Analysis Main findings 
Kmet et al9 
score and 
quality issues 
Duncan 
RE et al. 
(2007)11  
Australia 8 17-25 
years 
Huntington 
disease 
To explore the 
experience of 
predictive 
genetic testing 
for HD from  
young persons’ 
perspectives 
and document 
the impact that 
testing has 
upon various 
aspects of 
young peoples’ 
lives 
 
Thematic analysis For some of the young 
people interviewed, 
uncertainty about their 
genetic status 
constituted a barrier in 
their lives and 
prevented them from 
moving forward. Testing 
in similar circumstances 
may therefore allow 
other young people to 
move forward with their 
lives. 
Score =80% 
Duncan 
RE et al. 
(2008)16 
 
Australia 18 14-26 
years 
Huntington 
disease and 
familial 
adenomatous 
polyposis 
To evaluate the 
potential 
effects 
associated with 
predictive 
genetic tests in 
young people 
Grounded theory The results were 
analysed in two 
categories: harms and 
benefits. These 
categories have been 
separated into three 
sub-categories: a) 
experiences relating to 
a gene-positive test 
result; b) experiences 
relating to a gene-
negative test result; c) 
experiences relating to 
the testing process in 
general. 
 
Score =70% 
Duncan  
RE et al. 
(2010)12 
Australia 10 12-25 
years 
Familial 
adenomatous 
polyposis 
To evaluate 
some of the 
key ethical 
challenges 
Combination of 
interpretative 
content analysis 
and thematic 
Five themes emerged: 
1) the significance of 
the test; 2) young 
people’s lack of 
Score =50% 
Sampling 
strategy 
verification 
associated with 
predictive 
genetic testing 
for FAP in 
young people 
analysis involvement in the 
decision to be tested; 3) 
young people’s limited 
understanding; 4) 
provision of the blood 
test at the first visit; 5) 
group testing of family 
members. These 
themes highlighted key 
ethical challenges. 
From these themes, 
authors draw eight 
recommendations for 
future practice to 
provide 
developmentally 
appropriate care to 
young adults 
undergoing predictive 
genetic testing. 
 
procedures to 
establish 
credibility of the 
study were not 
well  described. 
Hamilton 
R  et al. 
(2009)17  
United 
States of 
American 
and 
Canada 
44 18-39 
years 
Hereditary 
breast and 
ovarian cancer 
To describe the 
decisional 
process of 
young women 
with increased 
risk for HBOC 
Grounded theory Four life trajectories that 
influenced the decision 
in young women to 
have genetic testing 
and subsequent risk 
reduction decisions 
after receiving a 
positive mutation result: 
1) long-standing 
awareness of breast 
cancer in the family; 2) 
loss of one’s mother to 
breast cancer at a 
young age; 3) 
expression of concern 
Score =90% 
by  a health care 
provide; 4) personal 
diagnosis of breast 
cancer. Understanding 
possible influences 
behind decision making 
for genetic testing and 
risk reduction in young 
women may assist 
health care providers in 
offering age appropriate 
guidance and support. 
 
Hamilton 
R (2012)18  
United 
States of 
American 
and 
Canada 
44 18-39 
years 
Hereditary 
breast and 
ovarian cancer 
To explore how 
young women 
live with a 
BRCA mutation 
Grounded theory Among 13 unmarried 
women, issues of when 
to disclose information 
about their genetic risk 
with their partners were 
discussed. 24 women 
who had children 
reported “staying alive” 
for their children as a 
primary goal; on the 
other hand women 
without children 
reported an urgency to 
have children. Several 
of the 21 who had a 
breast cancer diagnosis 
said knowledge of their 
genetic risk influenced 
their decision to 
undergo prophylactic 
mastectomy. 
 
Score =65% 
The sampling 
strategy, data 
collection 
methods and 
analytic methods 
are not well  
described.  
Hoskins United 32 21-25 Hereditary To explore  Young adults expressed Score =90% 
LM et al. 
(2014) 
States of 
American 
years breast and 
ovarian cancer 
patient-
centered 
perspective on 
the dilemma 
faced by 18 to 
24 years old as 
they 
considered 
BRCA1/2 
genetic testing 
and risk 
management 
 
needs for greater clarity 
in recommendations for 
screening and 
prevention before age 
25, and ongoing contact 
with providers to 
discuss risk 
management protocols. 
Macrae L 
et al. 
(2013)13  
Canada 8 22-37 
years 
Hereditary 
breast and 
ovarian cancer 
To assess the 
experiences of 
those mutation-
negative young 
women 
Thematic analysis To investigate the 
experience of BRCA 
mutation-negative 
young women, eight 
themes were analysed: 
1) timing; 2) disclosure; 
3) risk perceptions; 4) 
cancer worry; 5) cancer 
burden; 6) hope; 7) 
plans for the future; 8) 
explanatory models for 
mutation status. These 
young women were 
likely still affected by 
the degree of cancer 
history in their family, 
even with their 
understanding of the 
genetic contribution to 
disease. 
 
Score =90% 
MacLeod  
R et al. 
United 
Kingdom 
36 15-31 
years 
Huntington 
disease,  
To evaluate the 
motivation of 
Interpretative 
Phenomenological 
Young adults saw the 
value of pretest 
Score =90% 
(2014) Hereditary 
breast and 
ovarian cancer, 
hypertrophic 
cardiomyopathy 
or dilated 
cardiomyopathy,  
young adults to 
be tested when 
young, their 
experiences of 
the counselling 
process and 
the advice they 
would offer to 
health 
professionals 
and other 
young adults 
considering 
testing 
Analysis counselling not in 
facilitating a decision, 
but rather as a source 
of information and 
support. Differences 
emerged between the 
disease groups in terms 
of parental attitudes to 
testing. Parents in 
families  with familial 
cardiomyopathy were a 
strong influence in 
favour of testing, in 
HBOC the decision was 
autonomous but 
congruent with the 
parents’ view, and in 
HD the decision was 
autonomous and 
sometimes went against 
the opinions of 
relatives. 
 
Mand C et 
al. 
(2013)14 
 
Australia 9 17-21 
years 
Huntington 
disease, 
Autosomal 
Dominant 
Cerebellar 
Ataxia, Lynch 
Syndrome, 
Hereditary 
breast and 
ovarian cancer , 
Hereditary 
Diffuse Gastric 
Cancer 
To assess the 
experiences of 
young people 
who request a 
predictive 
genetic testing 
Thematic analysis Three themes emerged: 
1) life before the test; 2) 
the battle to be tested; 
3) living with the 
knowledge. The results 
convey young adults, 
from families affected 
by genetic conditions, 
might possess task-
specific competence 
relating to decision 
making about predictive 
testing. 
Score =50% 
The design and 
connection to a 
theoretical 
framework is not 
completely 
described, and 
the verification 
procedures to 
establish 
credibility of the 
study were not 
described. 
 Patenaude 
AF et al. 
(2013)15 
 
United 
States of 
American 
40 18-24 
years 
Hereditary 
breast and 
ovarian cancer 
To evaluate 
what daughters 
understand 
about their 
50% chance of 
carrying BRCA 
mutation and 
about risk 
reduction or 
management 
options for 
mutation 
carriers. To 
assess the 
extent and 
nature of 
daughters’ 
cancer-related 
distress and 
the effects of 
knowing 
mother’s 
mutation status 
on daughters’ 
future plans. 
Thematic analysis Daughters of mothers 
who tested positive for 
a mutation in BRCA 
genes showed scarce 
genetic knowledge. 
Also, the genetic 
information was raised 
by young women 
regarding their future 
plans, such as 
childbearing.  
Score =70% 
Werner-
Lin A et al. 
(2012)19  
United 
States of 
American 
32 18-24 
years 
Hereditary 
breast and 
ovarian cancer 
To build on and 
increase 
findings of 
experiences of 
BRCA 1/2 
mutation 
carriers in their 
reproductive 
years by 
focusing on 
Grounded theory Feeling vulnerable to a 
cancer diagnosis were 
described by 
participant.  Also, they 
described a quandary 
regarding their care, a 
wide range of genetic 
and health literacy. 
Several young women 
contemplated risk-
Score =80% 
 0 
1 
those 
challenges 
specific to 18-
24 year-olds 
reducing mastectomy 
before age 25. Parents 
were a primary source 
of emotional and 
financial support for 
young adults. 
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